Oramed Pharmaceuticals (ORMP) Asset Writedowns and Impairment (2012)

Oramed Pharmaceuticals (ORMP) posted Asset Writedowns and Impairment of $141143.0 for Q3 2012, up 227.39% on a QoQ basis from $43111.0 in Q1 2012.

Oramed Pharmaceuticals (ORMP) Asset Writedowns and Impairment (2012) Analysis & Trends

Oramed Pharmaceuticals' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $141143.0 for Q3 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Oramed Pharmaceuticals	170.25 Mn	170.25 Mn	-

Download Data